Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.
Laidlaw SM. et al, (2025), Microbiol Spectr, 13
Europe needs a sustainably funded influenza research and response network.
Krammer F. et al, (2025), Lancet Infect Dis, 25, 369 - 372
Ebola disease: bridging scientific discoveries and clinical application.
Rojek A. et al, (2025), Lancet Infect Dis, 25, e165 - e176
Embedding treatment in stronger care systems.
Rojek A. et al, (2025), Lancet Infect Dis, 25, e177 - e188
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2025), EClinicalMedicine, 81
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.
Hassan MZ. et al, (2025), Lancet Reg Health Southeast Asia, 33
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Pesonel E. et al, (2025), Clin Infect Dis
The Modern Landscape of Ebola Disease 1 Ebola disease: bridging scientific discoveries and clinical application
Rojek A. et al, (2025), LANCET INFECTIOUS DISEASES, 25, e165 - e176
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.
Chan XHS. et al, (2024), Lancet Microbe
14.1 In Practice: RECOVERY Trial
Horby P. et al, (2024), Principles and Practice of Emergency Research Response
In Practice: RECOVERY Trial
Horby P. et al, (2024), Principles and Practice of Emergency Research Response
Group sequential designs for clinical trials when the maximum sample size is uncertain.
Yarahmadi A. et al, (2024), Stat Med
Presentation and outcomes of Lassa fever in children in Nigeria: a prospective cohort study (LASCOPE).
Duvignaud A. et al, (2024), J Pediatric Infect Dis Soc
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Vale C. et al, (2024), Lancet Diabetes & Endocrinology
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.
Randremanana RV. et al, (2024), Trials, 25